SyntekaBio Inc
SyntekaBio, Inc. operates as an artificial intelligence new drug development company based on genomic big data primarily in South Korea. It derives new drug candidates using DeepMatcher, an AI drug development platform that combines new drug development technology and genomic big data technology. The company also researches and develops biomarker detection for individual cancer drug screening, di… Read more
SyntekaBio Inc (226330) - Net Assets
Latest net assets as of September 2025: ₩11.90 Billion KRW
Based on the latest financial reports, SyntekaBio Inc (226330) has net assets worth ₩11.90 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩33.49 Billion) and total liabilities (₩21.59 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩11.90 Billion |
| % of Total Assets | 35.53% |
| Annual Growth Rate | N/A |
| 5-Year Change | -39.95% |
| 10-Year Change | N/A |
| Growth Volatility | 1013.33 |
SyntekaBio Inc - Net Assets Trend (2017–2024)
This chart illustrates how SyntekaBio Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SyntekaBio Inc (2017–2024)
The table below shows the annual net assets of SyntekaBio Inc from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩24.94 Billion | -20.13% |
| 2023-12-31 | ₩31.23 Billion | -0.74% |
| 2022-12-31 | ₩31.46 Billion | +13.88% |
| 2021-12-31 | ₩27.63 Billion | -33.49% |
| 2020-12-31 | ₩41.54 Billion | -9.91% |
| 2019-12-31 | ₩46.11 Billion | +2708.68% |
| 2018-12-31 | ₩1.64 Billion | +158.83% |
| 2017-12-31 | ₩-2.79 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to SyntekaBio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6402510638000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩101.24 Billion | 405.87% |
| Total Equity | ₩24.94 Billion | 100.00% |
SyntekaBio Inc Competitors by Market Cap
The table below lists competitors of SyntekaBio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Wearable Devices Ltd.
NASDAQ:WLDSW
|
$28.61 Million |
|
It's Skin Co Ltd
KO:226320
|
$28.64 Million |
|
Crest Ventures Limited
NSE:CREST
|
$28.66 Million |
|
Batavia Prosperindo Int
JK:BPII
|
$28.66 Million |
|
Equity Metals Corporation
OTCQB:EQMEF
|
$28.61 Million |
|
1480
TWO:1480
|
$28.61 Million |
|
RSWM Limited
NSE:RSWM
|
$28.60 Million |
|
The Brooker Group Public Company Limited
BK:BTC
|
$28.59 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SyntekaBio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 31,228,289,960 to 24,943,253,090, a change of -6,285,036,870 (-20.1%).
- Net loss of 7,213,184,100 reduced equity.
- Share repurchases of 262,000,000 reduced equity.
- New share issuances of 262,000,000 increased equity.
- Other factors increased equity by 928,147,230.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-7.21 Billion | -28.92% |
| Share Repurchases | ₩262.00 Million | -1.05% |
| Share Issuances | ₩262.00 Million | +1.05% |
| Other Changes | ₩928.15 Million | +3.72% |
| Total Change | ₩- | -20.13% |
Book Value vs Market Value Analysis
This analysis compares SyntekaBio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.03x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩-242.53 | ₩3315.00 | x |
| 2018-12-31 | ₩142.67 | ₩3315.00 | x |
| 2019-12-31 | ₩3505.21 | ₩3315.00 | x |
| 2020-12-31 | ₩3108.82 | ₩3315.00 | x |
| 2021-12-31 | ₩2046.45 | ₩3315.00 | x |
| 2022-12-31 | ₩2327.37 | ₩3315.00 | x |
| 2023-12-31 | ₩2050.38 | ₩3315.00 | x |
| 2024-12-31 | ₩1634.71 | ₩3315.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SyntekaBio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -28.92%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5966.88%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.75x
- Recent ROE (-28.92%) is below the historical average (3.68%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | -13302.49% | 0.02x | 0.00x | ₩-5.51 Billion |
| 2018 | 228.21% | 1307.34% | 0.02x | 7.38x | ₩3.58 Billion |
| 2019 | -49.81% | -4977.80% | 0.01x | 1.04x | ₩-27.58 Billion |
| 2020 | -15.62% | -1064.13% | 0.01x | 1.08x | ₩-10.64 Billion |
| 2021 | -53.58% | -4674.69% | 0.00x | 2.46x | ₩-17.57 Billion |
| 2022 | -14.32% | -1846.96% | 0.00x | 1.77x | ₩-7.65 Billion |
| 2023 | -36.50% | -9235.91% | 0.00x | 1.69x | ₩-14.52 Billion |
| 2024 | -28.92% | -5966.88% | 0.00x | 1.75x | ₩-9.71 Billion |
Industry Comparison
This section compares SyntekaBio Inc's net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $53,806,944,127
- Average return on equity (ROE) among peers: -21.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SyntekaBio Inc (226330) | ₩11.90 Billion | 0.00% | 1.81x | $28.61 Million |
| BIT Computer Co. Ltd (032850) | $66.21 Billion | 8.36% | 0.21x | $42.37 Million |
| ezCaretech Co. LTD (099750) | $34.16 Billion | -28.06% | 0.73x | $8.27 Million |
| Carelabs Co.Ltd (263700) | $10.40 Billion | 18.59% | 0.52x | $22.17 Million |
| Deep Noid Inc. (315640) | $27.18 Billion | -24.79% | 0.27x | $42.49 Million |
| Lunit Inc. (328130) | $235.11 Billion | -15.65% | 0.14x | $590.83 Million |
| Vuno Inc. (338220) | $5.42 Billion | -109.11% | 0.38x | $139.34 Million |
| LifeSemantics Corp. (347700) | $-1.84 Billion | 0.00% | 0.00x | $189.97 Million |